Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
3,828 JPY | -0.52% | +2.57% | +18.81% |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
Strengths
- The company appears to be poorly valued given its net asset value.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- For the past twelve months, EPS forecast has been revised upwards.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- The company is not the most generous with respect to shareholders' compensation.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+18.81% | 1.54B | C | ||
+18.64% | 71.4B | C+ | ||
-6.00% | 23.08B | C+ | ||
+2.93% | 8.55B | C | ||
+9.32% | 8.43B | B | ||
-25.47% | 7.46B | B- | ||
+13.19% | 5.23B | B- | ||
+1.58% | 4.29B | B- | ||
+5.71% | 3.89B | B+ | ||
+0.48% | 4.03B | B |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 8129 Stock
- Ratings Toho Holdings Co., Ltd.